Novartis announces a large-scale U.S. expansion with new facilities in North Carolina, aiming to boost domestic production, create thousands of jobs, and strengthen its long-term American manufacturing footprint.

Novartis has unveiled a major expansion plan in North Carolina, marking one of its most significant U.S. manufacturing commitments in recent years.

The company confirmed that the new development will be part of its broader five-year, $23 billion investment strategy aimed at strengthening its American operations.

The upcoming manufacturing hub is expected to generate 700 direct jobs, while an additional 3,000 indirect roles are projected across the broader supply chain.

These new opportunities are planned to unfold by 2030, positioning North Carolina as a growing center for pharmaceutical innovation and production.

The announcement follows a recent preliminary trade agreement between the United States and Switzerland, designed to ease tariff pressures and encourage deeper economic collaboration.

Under the agreement, U.S. tariffs on Swiss goods are expected to fall from 39% to 15%, creating a more favorable environment for cross-border investment.

In return, Swiss companies, including Novartis, have pledged a collective investment of $200 billion into the U.S. economy by 2028.

Novartis’ newly planned hub will include two advanced facilities in Durham, focused on biologics manufacturing and sterile packaging for high-precision medical products.

A separate site will be located in Morrisville, dedicated to solid dosage production and packaging across key therapeutic areas.

The company also plans to expand its existing Durham campus, adding new capabilities to support sterile biologics filling and quality-controlled production.

These expansions are intended to strengthen Novartis’ manufacturing resilience, making it possible for the company to produce all core U.S. medicines domestically.

The focus on domestic output reflects a broader shift across the pharmaceutical sector, as global supply chain disruptions have pushed companies to localize critical operations.

Novartis emphasized that increasing U.S. manufacturing capacity is central to ensuring consistent access to essential treatments, particularly in high-demand categories.

The new facilities are expected to be operational between 2027 and 2028, with construction, hiring, and training phases rolling out gradually across the next several years.

Industry analysts see the expansion as a strategic move, strengthening the company’s presence in a region already known for biotech leadership.

North Carolina’s Research Triangle has long attracted major pharmaceutical, biotech, and research institutions, making it an ideal environment for large-scale development.

The new investment is also expected to stimulate additional activity in related sectors, including packaging, logistics, scientific equipment, and high-skilled technical services.

Local officials welcomed the announcement, viewing it as a significant boost to the regional economy and a long-term opportunity for workforce growth.

Novartis stated that the expansion is designed not only to increase capacity, but also to support innovation in biologics, sterile production, and advanced pharmaceutical technologies.

The company aims to build modern, efficient, and highly regulated facilities capable of meeting future demand for complex medical treatments.

Beyond boosting production, the initiative aligns with broader U.S. objectives to localize essential medicine manufacturing and reduce reliance on overseas suppliers.

The collaboration between the Swiss and U.S. governments marks a shift toward deeper economic alignment, reinforcing trade stability and long-term investment channels.

With construction timelines already mapped out, Novartis is preparing to begin the next phase of planning and regional coordination.

As the project progresses, the company says its focus will remain on delivering state-of-the-art manufacturing systems equipped for future medical and scientific advancements.

The North Carolina expansion is expected to play a decisive role in shaping Novartis’ U.S. presence over the next decade, marking a major step in its global growth strategy.

In a landmark move to advance treatments for rare muscle disorders, Novartis takes a major step toward expanding its innovation footprint in the U.S. and reshaping the future of genetic medicine.

Swiss pharmaceutical giant Novartis has announced its plan to acquire U.S.-based biotech company Avidity Biosciences in a deal valued at approximately $12 billion in cash.

The acquisition highlights Novartis’ strong commitment to accelerating breakthroughs in rare diseases while broadening its research and commercial presence in the United States.

Under the agreement, Avidity shareholders will receive $72 per share in cash, marking a 46% premium from the company’s recent closing value. This acquisition continues Novartis’ momentum of strategic partnerships and purchases aimed at strengthening its long-term drug pipeline.

The acquisition will allow Novartis to tap into Avidity’s innovative RNA-based delivery platform, which enables the direct targeting of muscle tissues — a crucial advancement for treating complex neuromuscular diseases.

Avidity’s portfolio includes multiple first-in-class drug candidates that aim to address conditions that currently have limited or no treatment options.

Avidity Biosciences, based in San Diego, California, has gained recognition for its pioneering work in precision medicine. Its leading drug candidate, Del-zota, is in early-to-mid-stage development for a rare form of Duchenne muscular dystrophy.

Alongside this, the company is also developing additional treatments for other severe muscle conditions that impact mobility and quality of life.

As part of the deal, Avidity will separate its early-stage precision cardiology programs into a new publicly traded company, Spinco.

This move allows Novartis to focus its investment and expertise on Avidity’s advanced neuromuscular pipeline, while Spinco will continue exploring innovative cardiovascular therapies.

Kathleen Gallagher, Avidity’s chief program officer, will lead Spinco as it moves forward independently.

For Novartis, this acquisition represents more than an expansion of its portfolio — it reflects a clear strategic vision. The company aims to fill critical gaps in treatment for rare diseases and strengthen its scientific leadership in genetic and RNA-based medicines.

The integration of Avidity’s technology will enable Novartis to accelerate the development of next-generation therapies that can reach patients faster and more effectively.

The timing of the deal is significant. Global pharmaceutical markets are navigating shifting trade policies and growing emphasis on localized production.

Novartis’ increased U.S. presence positions it strongly amid these changes, reinforcing its role as a reliable partner in healthcare innovation.

The acquisition also aligns with the company’s ongoing efforts to diversify its revenue streams as some of its major drugs approach patent expirations.

In recent years, Novartis has actively pursued a series of targeted acquisitions designed to build leadership across key therapeutic areas. These include its $3.1 billion purchase of Anthos Therapeutics to boost cardiovascular drug development and a $1.7 billion deal with Regulus Therapeutics to strengthen its renal care pipeline.

Its partnership with Matchpoint Therapeutics, worth up to $1 billion, further enhanced its focus on developing oral medicines for inflammatory diseases.

The Avidity acquisition fits seamlessly into this pattern — combining Novartis’ global expertise with Avidity’s cutting-edge science to push the boundaries of what’s possible in rare disease treatment.

Analysts see this as a bold and timely step that underscores Novartis’ long-term commitment to medical innovation and patient well-being.

Beyond its scientific impact, the deal also sends a strong message about Novartis’ investment in U.S. biotech. By supporting Avidity’s continued work in San Diego and enabling Spinco’s independent growth, the company is contributing to the vibrancy and competitiveness of America’s life sciences sector.

As the global healthcare landscape evolves, Novartis continues to lead with vision and purpose. The acquisition of Avidity Biosciences represents not only financial growth but a deeper mission — to deliver hope and healing to patients who have long awaited effective therapies for rare, life-altering diseases.

With this move, Novartis reinforces its identity as a global innovator committed to turning groundbreaking science into real-world solutions.

The company’s continued expansion into precision and genetic medicine ensures that its legacy of excellence will remain strong for decades to come.